189results about "Antigen/adjuvant combination ingredients" patented technology

An immune-based approach for treating and preventing skin cancer by boosting T cell immunity against commensal HPV present in the skin. Accordingly, provided herein are compositions comprising: (i) a plurality of antigenic peptides, each comprising a sequence of 9 to 30 amino acids derived from a protein from a commensal human papillomavirus; (ii) a plurality of live or live-attenuated commensal human papillomaviruses; (iii) a plurality of antigenic proteins from a commensal human papillomavirus, preferably in a virus-like particle; and / or (iv) a plurality of nucleic acids encoding (a) a plurality of antigenic peptides, each comprising a sequence of 9 to 30 amino acids derived from a protein from a commensal human papillomavirus, or (b) a plurality of antigenic proteins from a commensal human papillomavirus; and optionally a T cell adjuvant that increases T cell responses to the antigenic peptides.

Embodiments of the present invention generally relate to novel immunostimulatory compositions of use to stimulate non-specific immune responses in a subject. In certain embodiments, immunogenic compositions disclosed herein can be directed to use in the eye of a subject. In some embodiments, the immunogenic compositions disclosed herein enhance non-specific immune responses in the eye of a subject to treat or reduce the risk of onset of an eye condition. In other embodiments, compositions disclosed herein can be used to treat eye infections due to a microorganism, tumors of the eye, as well as, chronic wounds or infections of the eye. In some embodiments, immunogenic ocular formulations disclosed herein include combinations of agents for prolonged exposure to the eye for improved outcomes.

The present invention relates to a flagellin fusion protein and the use thereof, and, more specifically, to a fusion protein comprising a human IgG4 Fc variant and the use thereof using toll-like receptor 5 (TLR5) stimulation activity, wherein the human IgG4 Fc variant has mutation preventing a Fab-arm exchange.

The present invention is based on the discovery that incubating Cryptosporidium gp40 protein with aziridine significantly increases the immunogenicity of the Cryptosporidium gp40 protein. When used as a vaccine, this allows for a reduced dose, thereby improving economic feasibility and safety. As a result, aziridine-treated gp40 can now be used as a safe and effective subunit vaccine for humans or non-human animals against cryptosporidiosis. Specifically, in the case of neonatal ruminants, vaccination via colostrum transfer has been shown to be highly effective in reducing the clinical signs of cryptosporidiosis, particularly diarrhea.

In one aspect, the disclosure relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide, and methods of use thereof. The disclosure further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and / or prevent diseases or disorders, e.g., infectious diseases.

The present invention provides a vaccine composition comprising a therapeutically effective amount of whole influenza virus, split influenza virus, virus like particle (VLP) or a combination thereof wherein one or more surface viral glycoproteins of the whole influenza virus, split influenza virus or VLP is partially glycosylated; and wherein the whole influenza virus and the split influenza virus has been attenuated or inactivated. The present invention also provides a method of preparation of the vaccine comprising the steps of injecting working virus seed with an inhibitor of the mannosidase into embryonated chicken egg to inoculate the embryonated chicken egg; incubating the inoculated embryonated chicken egg to propagate the working vims; harvesting allantonic fluids from the inoculated embryonated chicken egg; concentrating and clarifying the harvested allantonic fluids; purifying the concentrated and clarified allantonic fluids using sucrose density centrifugation; applying deglycosylation enzyme to the purified allantonic fluid to partially glycosylate viral surface glycoprotein of the propagated vims within the purified allantonic fluid; removing deglycosylation enzyme from whole vims with partially glycosylated viral surface glycoprotein; and inactivating the vims. The present invention further provides a method of treatment for prevention of influenza infection comprising the step of administering any embodiment of the vaccine of the present invention to a subject.

Aspects of the invention are drawn to compositions and methods for modulating CD8 Treg mobilization in the treatment of autoimmune disorders, rejection of transplanted organs and cancer.

Chemical compositions and / or mixtures that allow nucleic acid to remain stable at ambient temperatures. The disclosed technology includes a solution and manufacturing methods thereof. The solution includes a chelating agent, a buffering agent, and a salt. The solution is configured to protect RNA and / or an RNA-based vaccine added to the solution and prevents or reduces degradation of the RNA and / or the RNA-based vaccine for a duration of 2 to 180 days over a temperature range of −20 degrees C. to +38 degrees C. The chelating agent can comprise ethylenediaminetetraacetic acid (EDTA). The buffering agent can comprise tris(hydroxymethyl)aminomethane (TRIS). The salt can comprise NaCl. The solution is configured to preserve an injectable mRNA vaccine added to the solution, and the solution is safe for injection into mammals.

The present application provides enhanced APCs for use in the treatment of HPV-associated cancers. The enhanced APC is capable of activating T cells in an HLA-agnostic manner and is derived from an input APC in which at least one nucleic acid encoding an HPV antigen has been delivered within the cell. In some aspects, the enhanced APC is administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1 / PD-L1 and / or an antagonist of CTLA-4.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

To provide a novel immune enhancer composition which induces a strong cellular immune response by direct activation of unconventional T cells and conventional T cells in bovine and pig immune cells, and a vaccine composition including the immune enhancer composition.SOLUTION: An immune enhancer composition comprises RAR-related orphan receptor gamma t, which is a T cell agonist, as an active ingredient.SELECTED DRAWING: Figure 8b

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

Disclosed is a vaccine adjuvant comprising at least one inverse microlatex comprising at least one oil, at least one surfactant, at least one polymer, such as, for example, a fully or partially neutralized polyacrylate in the form of an alkali metal salt or an ammonium salt, which can be completely sterilized by filtration or by heating in an autoclave and can be emulsified in one step with an aqueous phase comprising only the vaccine antigen.

To provide pharmaceutically acceptable compositions that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against therapeutic agents.SOLUTION: The present invention provides a composition comprising a compound of Formula 1, where m is an integer from about 1 to 100; X comprises an antigen against which a patient develops an unwanted immune response, or a tolerogenic portion thereof; or X comprises an antibody, antibody fragment or ligand that specifically binds a circulating protein or peptide or antibody; Y comprises a linker moiety; and Z comprises a liver-targeting moiety.SELECTED DRAWING: Figure 2

Disclosed herein are polynucleotides encoding one or more rumen-associated antigens, and polypeptides encoded by the polynucleotides. Also provided herein are compositions comprising the polynucleotides, and methods of making and using the compositions.

A fusion polypeptide comprising an extracellular domain of human CTLA-4 and an extracellular domain of human PD-L1 and an immune composition comprising such for use in treating cancer in animals such as dogs and cats.

The present invention relates to stable vaccine formulations for administration via a microprojection array in which the microprojections are densely packed and in which the vaccine formulations are rapidly sprayed or layered on to the microprojections in relatively small amounts such that the formulations dry rapidly. The present invention relates in particular to stabilized measles and rubella vaccines delivered by high density micro-array MAPs (HDMAP).

The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3′ untranslated region (3′UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.

To provide Epstein-Barr virus (EBV) polypeptides and their use in eliciting antibodies against EBV.SOLUTION: Antigenic Epstein-Barr virus (EBV) polypeptides comprising an EBV gL polypeptide and an EBV gH polypeptide, a linker having a length of at least 15 amino acids separating the EBV gL polypeptide and the EBV gH polypeptide, are provided. Antigenic EBV polypeptides comprising an EBV polypeptide and a ferritin protein are also provided.SELECTED DRAWING: None

The present disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies to EBV. Antigenic polypeptides, including EBV polypeptides and ferritin proteins, are also disclosed.

The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5′ copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5′ copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and / or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

The present disclosure relates to methods and agents for antigen vaccination and induction of effective antigen-specific immune effector cell responses, such as T cell responses. These methods and agents are particularly useful for treating diseases characterized by disease cells expressing an antigen to which immune effector cells are directed. In some embodiments, the present disclosure relates to a method comprising administering to a subject (i) a non-immunogenic RNA encoding a peptide or polypeptide comprising an epitope for inducing an immune response against the antigen in a subject, i.e., a non-immunogenic RNA encoding a vaccine antigen, and (ii) a PD-1 axis binding antagonist, such as an anti-PD-1 antibody and / or an anti-PD-L1 antibody.

Compositions comprising an antigen, a carbohydrate, and a metabolizable oil, methods of administering such compositions to a subject, methods of making such compounds, and related compositions, methods, and uses.

This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

The present invention provides phagocytic particles for treating or preventing cancer in a subject, wherein the phagocytic particle comprises a core and a neoantigen construct tightly associated with the core, and wherein the neoantigen construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of a portion of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the portion of the protein or peptide has at least one somatically mutated amino acid. The present invention also relates to an injectable pharmaceutical composition for treating or preventing cancer.

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

To provide a vaccine against Mycoplasma hyopneumoniae (Mhyo), which does not contain, as an adjuvant, a non-self compound having a site effect such as mineral and vegetable oils, non-natural polymers and aluminum hydroxide.SOLUTION: The vaccine comprises nanoparticles bound to Mycoplasma hyopneumoniae bacterin, wherein the nanoparticles comprise a cationic polysaccharide and an anionic phospholipid.SELECTED DRAWING: None